2014
Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance
Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. Journal Of Neuro-Oncology 2014, 121: 441-449. PMID: 25403507, PMCID: PMC4323763, DOI: 10.1007/s11060-014-1658-0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBrain NeoplasmsConvectionDrug Delivery SystemsFerric CompoundsGlioblastomaHumansImage Processing, Computer-AssistedLactic AcidMagnetic Resonance ImagingNanoparticlesNeuroimagingPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRatsRats, Sprague-DawleyConceptsBrain-penetrating nanoparticlesSuperparamagnetic iron oxideEfficient deliveryDrug-loaded nanoparticlesDistribution of nanoparticlesTransverse relaxivityPLGA nanoparticlesNanoparticlesConvection-enhanced deliveryDelivery platformFuture clinical applicationsUniversal tumor recurrenceClinical translationSignal attenuationDetection modalitiesIron oxideSame morphologyParticle distributionDeliveryGroundbreaking approachClinical applicationRelevant volumesRelaxivityTreatment of GBMOxide
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original Research
2010
Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors
Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, Saltzman WM. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Delivery And Translational Research 2010, 1: 34-42. PMID: 21691426, PMCID: PMC3117592, DOI: 10.1007/s13346-010-0001-3.Peer-Reviewed Original ResearchConvection-enhanced deliveryUnloaded nanoparticlesNanoparticle treatmentPolymer nanoparticlesNanoparticlesRelease nanoparticlesDrug loadingDrug releasePolymer deliveryDirect deliveryIntracranial tumorsSimultaneous controlIntracranial 9L tumorsLong-term survivorsDelivery of chemotherapyDeliveryDiffusional penetrationLocal tissue toxicityMedian survivalChemotherapy agentsTherapeutic benefitGlioblastoma multiformeGliosarcoma cellsTissue toxicityTumorsPhase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2007
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal Of Clinical Oncology 2007, 25: 837-844. PMID: 17327604, DOI: 10.1200/jco.2006.08.1117.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryIntracerebral convection-enhanced deliveryCintredekin besudotoxRecurrent malignant gliomaMalignant gliomasGlioblastoma multiformeMedian survivalCatheter placementTumor resectionInfusion durationProcedure-related adverse eventsFavorable risk-benefit profilePhase I clinical studyBetter drug distributionDirect intracerebral deliveryOptimal drug distributionOverall median survivalPortion of patientsRisk-benefit profileDevastating brain tumorDrug distributionAdverse eventsHigh tissue concentrationsIntracerebral deliveryTumor necrosis
2006
New methods for direct delivery of chemotherapy for treating brain tumors.
Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. The Yale Journal Of Biology And Medicine 2006, 79: 141-52. PMID: 17940624, PMCID: PMC1994797.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryBrain tumorsPrimary malignant brain tumorLocal deliveryBlood-brain barrierMalignant brain tumorsStandard chemotherapeutic drugsBrain cancer treatmentAnti-cancer therapyMedian survivalInfusion siteSevere formMalignant cellsNew delivery strategiesChemotherapy drugsChemotherapyDiagnostic imagingTumorsChemotherapeutic drugsCancer treatmentDrugsInvasive cellsSource of drugsDelivery strategiesBrain